MedTrace Logo

A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma

NCT01591044 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 301

Last updated 2016-09-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety, efficacy and tolerability of R940343 in the treatment of mild to moderate asthma.

Conditions

Interventions

DRUG

Placebo

1 puff bid or 2 puffs bid

DRUG

R940343 1mg

R343 1mg, 1 puff bid

DRUG

R940343 2mg

R343 2mg, 2 puffs bid

Sponsors & Collaborators

  • Rigel Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Elliott Grossbard, MD · Rigel Pharmaceuticals,Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01591044 on ClinicalTrials.gov